HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

John Jereb Selected Research

Pyrazinamide

2/2007Safety of the rifampin and pyrazinamide short-course regimen for treating latent tuberculosis infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


John Jereb Research Topics

Disease

5Tuberculosis (Tuberculoses)
10/2017 - 06/2004
2Latent Tuberculosis
10/2017 - 02/2007
1Acquired Immunodeficiency Syndrome (AIDS)
06/2010
1Infections
12/2005

Drug/Important Bio-Agent (IBA)

2GoldIBA
06/2010 - 12/2005
1rifapentine (Priftin)FDA Link
10/2017
1Isoniazid (Ftivazide)FDA LinkGeneric
10/2017
1Interferon-gamma (Interferon, gamma)IBA
06/2010
1PyrazinamideFDA LinkGeneric
02/2007
1Rifampin (Rifampicin)FDA LinkGeneric
02/2007
1Proteins (Proteins, Gene)FDA Link
12/2005
1Tuberculin (PPD)IBA
12/2005
1AntigensIBA
12/2005
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
10/2005

Therapy/Procedure

1Therapeutics
10/2005
1Drug Therapy (Chemotherapy)
06/2004